Buscar
Mostrando ítems 1-3 de 3
Is “Leptin Resistance” Another Key Resistance to Manage Type 2 Diabetes?
(Bentham Science Publishers, 2020)
Although novel pharmacological options for the treatment of type 2 diabetes mellitus (DM2) have been observed to modulate the functionality of several key organs in glucose homeostasis, successful regulation of insulin resistance (IR), body weight management, and pharmacological treatment of obesity remain notable problems in endocrinology. Leptin may be a pivotal player in this scenario, as an adipokine which centrally regulates appetite and energy balance. In obesity, excessive caloric intake promotes a low-grade inflammatory response, which ...
Obesidad Infantil: Un problema de pequeños que se está volviendo grande
(Cooperativa servicios y suministros 212518 RS, 2019)
La obesidad es una enfermedad crónica de comportamiento epidemiológico complejo
que se origina de la interacción entre factores genéticos y ambientales, entre los que destacan los patrones de alimentación y el consumo calórico diario, así como el grado de actividad física. Según la Organización Mundial para la Salud (OMS), la obesidad se define como una
acumulación anormal y excesiva de grasa corporal. Para el diagnóstico de esta condición en niños y adolescentes se utilizan tablas diseñadas por la OMS que definen a un individuo con sobrepeso ...
Microbiota and Diabetes Mellitus: Role of Lipid Mediators
(MDPI, 2020)
Diabetes Mellitus (DM) is an inflammatory clinical entity with different mechanisms involved in its physiopathology. Among these, the dysfunction of the gut microbiota stands out. Currently, it is understood that lipid products derived from the gut microbiota are capable of interacting with cells from the immune system and have an immunomodulatory effect. In the presence of dysbiosis, the concentration of lipopolysaccharides (LPS) increases, favoring damage to the intestinal barrier. Furthermore, a pro-inflammatory environment prevails, and a ...